Navigation Links
Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
Date:9/3/2012

MONTREAL and SCOTTSDALE, Ariz., Sept. 3, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) and Medicis Pharmaceutical Corporation (NYSE: MRX) today announced that they have entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Medicis for $44.00 per share in cash. The transaction, which values Medicis' common stock at approximately $2.6 billion, was unanimously approved by the Boards of Directors of both companies.  The $44.00 per share price represents a 39% premium to Medicis' closing share price on Friday, August 31, 2012, the last trading day prior to announcement, and a 31% premium to the three-month average trading price. The transaction is expected to close in the first half of 2013.

Medicis' portfolio includes leading prescription brands SOLODYN®, RESTYLANE®, PERLANE®, ZIANA®, DYSPORT® and ZYCLARA®. The pro forma net revenue for the combined company's dermatology and aesthetics businesses for 2012 is expected to exceed $1.7 billion within the United States.

Valeant's Chairman and Chief Executive Officer, J. Michael Pearson, said, "The acquisition of Medicis represents a significant next step in our journey to become the leader in dermatology by strengthening Valeant's presence in acne, actinic keratosis, aesthetic injectables and anti-virals, among others. Medicis' highly complementary portfolio of leading branded products and promising pipeline is a solid strategic fit, and we look forward to leveraging Medicis' well known and respected name in dermatology to drive long-term growth."

Jonah Shacknai, Chairman and Chief Executive Officer of Medicis, said, "Our Board of Directors b
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
2. Valeant Pharmaceuticals To Host Investor Day
3. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
4. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
5. Elevation Pharmaceuticals Presents Positive Phase 2b Results for EP-101 in COPD Patients at the European Respiratory Society Annual Congress
6. Lexicon Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
7. Novation Supports New Development in the U.S. Biosimilar Pharmaceuticals Market
8. Arena Pharmaceuticals to Present at Upcoming Investor Conferences
9. Isis Pharmaceuticals Demonstrates The Potential Of Single-Stranded RNA-Like Antisense Technology To Activate The RNAi Pathway
10. Optimer Pharmaceuticals to Present at September 2012 Investor Conferences
11. Global RFID in Healthcare and Pharmaceuticals Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading health care ... new IT value-added reseller (VAR) national contracts that expand ... and services at lower costs. These include manufacturer product ... as initiative assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its Israeli ... sophisticated agro-breeding solutions for plant breeders and researchers, today ... of directors appointed chemistry and pharmaceutical industry expert Dr. ... the board. From 1975 to 2012, Dr. ...
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... BOSTON, Jan. 27, 2011 Solos Endoscopy, Inc. (OTCPK: SNDY) ... the three months ended December 31, 2010 in the amount ... a result of instrument sales to over fifty Hospitals, Clinics, ... States. Solos looks towards continued growth in 2011 ...
... /PRNewswire-Asia/ -- Weikang Bio-Technology Group Co., Inc. ... the "Company"), a leading developer, manufacturer and marketer of ... and other health and nutritional products in the People,s ... products, Ranitidine Hydrochloride Capsule, has been added to the ...
Cached Medicine Technology:Solos Endoscopy, Inc. Reports $90,005 in Sales Revenue for Fourth Quarter 2010 2Weikang Bio-Technology Announces Inclusion of Ranitidine Hydrochloride Capsule on National Drug Reimbursement List 2Weikang Bio-Technology Announces Inclusion of Ranitidine Hydrochloride Capsule on National Drug Reimbursement List 3
(Date:7/9/2014)... type of lung cancer, researchers have uncovered mutations in ... tumors. The new knowledge may expand treatments for patients ... are available or are in clinical trials. , Reporting ... Cancer Genome Atlas (TCGA), including researchers at Washington University ... and other institutions, studied tumors from 230 patients with ...
(Date:7/9/2014)... -- Researchers from The Miriam Hospital have ... (COPD) who are also depressed have difficulty sticking ... be particularly true for women, and screening and ... part of treatment. The study and its findings ... . , Chronic obstructive pulmonary disease is ...
(Date:7/9/2014)... KNOXVILLEAmphibian declines and extinctions around the world have ... chytridiomycosis, but new research from the National Institute ... another pathogen, ranavirus, may also contribute. , ... that ranavirus, which causes severe hemorrhage of internal ... populations of wood frogs if they are exposed ...
(Date:7/9/2014)... retrospective study conducted by researchers at Tufts University School ... with intellectual and developmental disabilities, the likelihood of having ... care increased. The findings, published in the July/August issue ... improve interventions designed to address the oral health of ... the dental records of 107 patients at one of ...
(Date:7/9/2014)... allergic diseases has risen dramatically in Western societies. One ... to microorganisms and have fewer infections than previous generations, ... study by researchers at Sahlgrenska Academy, University of Gothenburg, ... maturation of the immune system in relation to allergic ... of the Vstra Gtaland Region, half of them on ...
Breaking Medicine News(10 mins):Health News:Lung cancer study hints at new treatments 2Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3
... APS Healthcare, a leading provider of specialty healthcare solutions, ... Services to deliver a unified total population health management ... the State consolidated its service providers from three to ... population that APS has been serving for the past ...
... PROSPECT, Ill., May 5 The National Association of ... May 5, 2009, examining the flagrant lawlessness of Web ... why this ,wild west, of an electronic marketplace is ... dead and injured patients," the paper asserts. The "State ...
... May 5 Tim Wentworth, group president, employer accounts, Medco ... to address the Bank of America/Merrill Lynch 2009 Health Care ... at the Palace Hotel in New York City, will begin ... officer, is also scheduled to attend.The presentation may be heard ...
... in one Minnesota city , , TUESDAY, May 5 (HealthDay ... known, another learning disability -- the inability to write ... new study suggests. , So-called written-language disorder is a ... epidemiologist at the Mayo Clinic and lead author of ...
... with elevated albumin levels were more likely to get ... News) -- A higher-than-normal level of the protein albumin ... clots in the deep veins of the lungs and ... (VTEs) include deep vein thrombosis (DVT), a clotting in ...
... NIH and Robert Wood Johnson Foundation-Sponsored Study Focuses on ... 5 Nearly 75 percent of children ages 3-6 ... getting enough exercise. A focus group study of child ... several reasons children are not getting as much physical ...
Cached Medicine News:Health News:Ohio Selects APS Healthcare to Manage Unified Population Health Management Program for State Employees 2Health News:NABP Position Paper Calls for Action Against Proliferation of Rogue Internet Drug Outlets 2Health News:NABP Position Paper Calls for Action Against Proliferation of Rogue Internet Drug Outlets 3Health News:Medco to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference 2Health News:Writing Disorder May Be Common Among Kids 2Health News:Urine Test Predicts Vein Clot Risk 2Health News:Urine Test Predicts Vein Clot Risk 3Health News:ABCs and No Skinned Knees: Study Reveals Various Barriers to Physical Activity in Child Care 2Health News:ABCs and No Skinned Knees: Study Reveals Various Barriers to Physical Activity in Child Care 3
Preclude Dura Substitute is the only non-biological membrane designed to "seal" around suture holes. 0.3 mm as nominal thickness....
... synthetic absorbable implant for the bridging of Dura ... is pliable, regardless of being used dry or ... must be taken, while implanting, to ensure that ... is oriented towards the cortex or the spinal ...
... is a non-absorbable dura ... purified polyesterurethane. Its microporous ... of fibroblast, supporting tissue ... minimizes suture channels, resulting ...
The Bovie IDS Series are the latest electrosurgical generators with fully digital implementation....
Medicine Products: